On this episode of ID the Future, internal medicine specialist Dr. Geoff Simmons speaks with host Andrew McDiarmid about his recent Evolution News article on the body’s response to the coronavirus, our immune system. It comprises an enormously complex enterprise with adaptive memory for millions of pathogens and the ability to keep on learning more. Researchers study it to learn how to create vaccines for diseases like COVID-19. Their work is one of intelligent design from start to finish. But, Simmons says, we ought to recognize that it starts with studying systems in our bodies that are even more intelligently designed. One might object that if our immune system were intelligently designed, it would be utterly immune to all pathogens, but such an objection makes theological or philosophical assumptions about the proper intentions of any would-be designer of life. The objection also overlooks the fact that we routinely recognize intelligent design in objects that are masterfully designed and yet not invulnerable to attack.
On this episode of ID the Future, biochemist Michael Behe and host Andrew McDiarmid discuss the anti-malarial drug chloroquine, now being investigated as a treatment for COVID-19, and how it may work on the cellular level against the coronavirus. The same drug was featured in Behe’s 2007 book The Edge of Evolution, as part of his demonstration that evolution has strict limits: It can do adaptive work for organisms with single mutations, but if just two coordinated mutations are required at once, evolution’s random processes have great difficulty even with natural selection helping them along. In cases where population sizes are enormous, as with malaria, it can eventually overcome the need for two simultaneous and coordinated mutations, but only just barely. Because the odds go up exponentially, three simultaneous coordinated mutations may be beyond the edge of evolution. What does all this bode for chloroquine and the coronavirus? Listen in as McDiarmid and Behe discuss.